Vaxart(VXRT)

View 1 open job Website LinkedIn Careers Page

Focus: Vaxart is a public biotechnology company pioneering oral vaccine technology for infectious diseases, operating at preclinical-to-Phase 2 scale with a diversified pipeline targeting respiratory and gastrointestinal pathogens.

Infectious Diseases Vaccines

Profile data last refreshed 2h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

Should You Work at Vaxart?

AI assessment

Vaxart offers a meaningful scientific and equity upside bet for early-career scientists willing to accept near-term cash runway and regulatory attrition risk; unsuitable for near-term compensation or role stability expectations.

Why Work Here

Emerging platform technology (oral vaccines) addressing large unmet needs in respiratory and GI infectious diseases with multiple Phase 1–2 programs in flight

Data completeness

5/9 — Partial

Company HealthSolid

Pipeline

Early-stage

40 total

LOE Risk

Protected

No near-term cliffs

Hiring

Slowing

Jobs decreasing

Pipeline & Clinical Trials

Laninamivir octanoate

Asthma

PHASE_1

VXA-G1.1-NN

Norovirus Infection

PHASE_1

Clinical Trials (1)

Help build intelligence for Vaxart

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company with direct capital markets access and recent revenue inflection ($29M in FY2025 vs. $7M in FY2024, 314% growth)

High R&D intensity (259%) signals aggressive investment in pipeline advancement and scientific innovation

Watch Out For

Severe cash burn: $66.9M net loss in FY2025 on only $29M revenue; cash runway of ~12 months at current burn rate ($64M cash position)
Pipeline heavily concentrated in Phase 1 (14 of 20 programs); zero Phase 3 candidates means years to potential value inflection and minimal near-term revenue catalysts
Recent BARDA funding cut (June 2026) signals loss of government support for vaccine programs, compounding cash pressure

Generated by Claude from Vaxart's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

NCT03897309Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

Phase 1

VXA-RSV-f Tablets

Respiratory Syncytial Virus (RSV)

PHASE_1

Clinical Trials (1)

NCT02830932Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Phase 1

VXA-BYW.10

Seasonal Influenza B

PHASE_1

Clinical Trials (1)

NCT02547792Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults

Phase 1

CS-8958 formulated as dry powder

Influenza

PHASE_1

VXA-A1.1 H1 Tablet Vaccine

Seasonal Influenza Preventative Vaccine Pharmacodynamics

PHASE_1

Clinical Trials (1)

NCT03121339Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults

Phase 1

BTA9881

Respiratory Syncytial Virus Infections

PHASE_1

Clinical Trials (1)

NCT00504907Safety Study of Oral BTA9881 to Treat RSV Infection

Phase 1

VXA-A1.1

Seasonal Influenza

PHASE_1

Clinical Trials (1)

NCT01761123Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum

Phase 1

VXA-CoV2-1

Covid19

PHASE_1

Clinical Trials (1)

NCT04563702Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects

Phase 1

CS-8958 formulated as dry powder

Influenza

PHASE_1

CS-8958

Influenza

PHASE_1

ND1.1

Avian Influenza

PHASE_1

Clinical Trials (1)

NCT01698060Immunogenicity of ND1.1 by Delivery Directly to the Ileum

Phase 1

ND1.1

Avian Influenza

PHASE_1

Clinical Trials (1)

NCT01335347Safety Study of an Oral Vaccine to Prevent Avian Influenza

Phase 1

VXA-A1.1 Oral Vaccine

Influenza

PHASE_1

Clinical Trials (1)

NCT01688297Safety Study of an Oral Vaccine to Prevent Seasonal Influenza

Phase 1

Midazolam 5mg Syrup

Drug-Drug Interaction Healthy Volunteers

PHASE_1

Clinical Trials (1)

NCT02204501A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers

Phase 1

Norwalk GI.1 Virus

Norovirus Infection

PHASE_1

Clinical Trials (1)

NCT03721549Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model

Phase 1

VXA-G1.1-NN Oral Vaccine

Norovirus Gastroenteritis

PHASE_1

Clinical Trials (1)

NCT03125473Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers

Phase 1

VXA-G1.1-NN

Norovirus Infections

PHASE_1

Clinical Trials (1)

NCT07254728A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants

Phase 1

VXA-G1.1-NN

Norovirus Infections

PHASE_1

Clinical Trials (1)

NCT05213728A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers

Phase 1

vapendavir 132 mg capsule

Healthy

PHASE_1

Clinical Trials (1)

NCT02877264A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers

Phase 1

VXA-G1.1-NN

Norovirus Gastroenteritis

PHASE_1

Clinical Trials (1)

NCT02868073Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

Phase 1

BTA-C585 oral capsules

Pharmacokinetics

PHASE_1

Clinical Trials (1)

NCT02668367Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers

Phase 1

VXA-GI.1.NN

Norovirus Infections

PHASE_1

Clinical Trials (1)

NCT04854746Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine

Phase 1

VXA-G1.1-NN

Norovirus Infections

PHASE_1

Clinical Trials (1)

NCT06944717A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old

Phase 1

BTA-C585 oral capsules

Pharmacokinetics

PHASE_1

Clinical Trials (1)

NCT02558413Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy Volunteers

Phase 1

Vapendavir 300 mg tablet

Healthy

PHASE_1

Clinical Trials (1)

NCT02101866A Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir Drug Formulations in Healthy Volunteers

Phase 1

VXA-G1.1-NN

Norovirus Infections

PHASE_1_2

Clinical Trials (1)

NCT04875676Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines

Phase 1/2

20 mg laninamivir octanoate

Influenza

PHASE_1_2

AP611074

Anogenital Warts

PHASE_1_2

Clinical Trials (1)

NCT01532102Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts

Phase 1/2

VXA-G1.1-NN

Norovirus Infections

PHASE_1_2

Clinical Trials (1)

NCT05212168Norovirus Challenge Study

Phase 1/2

Vapendavir

Rhinovirus

PHASE_2

Clinical Trials (1)

NCT03024177A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection

Phase 2

Vapendavir

Asthma

PHASE_2

Clinical Trials (1)

NCT02367313A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

Phase 2

Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose

Norovirus Infections

PHASE_2

Clinical Trials (1)

NCT05626803A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

Phase 2

VXA-CoV2-1.1-S

COVID-19

PHASE_2

Clinical Trials (1)

NCT05067933A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine

Phase 2

40 mg Laninamivir Octanoate

Influenza

PHASE_2

BTA798

Rhinovirus

PHASE_2

Clinical Trials (1)

NCT01175226A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

Phase 2

VXA-A1.1

Influenza

PHASE_2

Clinical Trials (1)

NCT02918006A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

Phase 2

AP611074 5% gel

Condyloma

PHASE_2

Clinical Trials (1)

NCT02724254A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Phase 2

VXA-CoV2-3.1

SARS-CoV2

PHASE_2

Clinical Trials (1)

NCT06672055A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

Phase 2

BTA-C585 oral capsule

Respiratory Syncytial Virus (RSV) Infection

PHASE_2

Clinical Trials (1)

NCT02718937Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study

Phase 2

Interview Prep Quick Facts

Portfolio: 34 clinical trials

Top TAs: Infectious Diseases, Respiratory, Gastroenterology

Publications: 26 in PubMed

SEC Filings: 2 available

Open Roles: 1 active job

Therapeutic Area Focus

Infectious Diseases

12 pipeline

Respiratory

3 pipeline

Gastroenterology

2 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$29M289%

R&D Spend

$74M(259%)9%

Net Income

-$67M

Hiring Trend

Stable

Open Roles

Added

-1

Filled/Removed

Based on last 4 crawl cycles

Risk Signals

BARDA funding cut in June 2026 implies likely near-term workforce optimization; no formal layoff disclosed in provided data.

Loss of government vaccine support plus minimal hiring and cash burn trajectory create elevated restructuring risk over next 12–18 months.

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Serum IgA proteomics reveals clonal composition and neutralization of dimeric and monomeric IgA repertoires against human norovirus.

Proceedings of the National Academy of Sciences of the United States of America

2026

PMID:42607213

Transfer of breast milk IgA to infants after oral bivalent norovirus vaccination of post-partum women.

NPJ vaccines

2026

PMID:41530181

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Vaxart(VXRT)

Should You Work at Vaxart?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Vaxart(10)

Open Jobs (1)

Vice President, Technical Operations

Financials (FY2025)

Hiring Trend

Risk Signals

Research Publications(10)